Academic Content and Language Evaluation of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6357)
All Articles published online
|
Publishing Process of This Article
|
Feb 26, 2022 (publication date) through Nov 6, 2025
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Shan BB, Li Y, Zhao C, An XQ, Zhang QM. Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive non-small-cell lung cancer: A case report. World J Clin Cases 2022; 10(6): 1883-1888 [PMID: 35317151 DOI: 10.12998/wjcc.v10.i6.1883] |
|
|
|
| ©2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Shan BB, Li Y, Zhao C, An XQ, Zhang QM. Efficacy of EGFR-TKI sequential therapy in patients with EGFR exon 19 insertion-positive non-small-cell lung cancer: A case report. World J Clin Cases 2022; 10(6): 1883-1888 [PMID: 35317151 DOI: 10.12998/wjcc.v10.i6.1883] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v10/i6/1883.htm |
| Number | Citing Articles |
| 1 |
Yang Li, Yunfeng Ni, Feng Lv, Yan Shi, Yedan Chen, Xiaoying Wu, Jiaohui Pang, Long Huang, Yang Shao, Tao Wang, Jie Min, Yang Song. Molecular characteristics and responses to EGFR tyrosine kinase inhibitors in non-small cell lung cancer patients with EGFR exon 19 insertions. BMC Medicine 2025; 23(1) doi: 10.1186/s12916-025-04075-1
|
| 2 |
Yingying Jiang, Xiaoxu Fang, Yan Xiang, Tingwen Fang, Jingwen Liu, Kaihua Lu. Afatinib for the Treatment of NSCLC with Uncommon EGFR Mutations: A Narrative Review. Current Oncology 2023; 30(6): 5337 doi: 10.3390/curroncol30060405
|
| 3 |
Thanh Ha Vu, Hoa Thai Thi Nguyen, To Van Ta, Minh Cong Truong, Thang Bui Xuan, Anh Tuan Nguyen, Cao Van Nguyen, Hang Thuy Thi Nguyen, Tuyet Thi Doan, Thanh Thi Vu, Dung Khac Dinh, Giang Vinh Le, Hung Huy Hoang, Chi Khanh Duong, Linh Khanh Dao. Real-World Evidence for First-Line afatinib in Advanced Non-Small Cell Lung Cancer With Uncommon Epidermal Growth Factor Receptor Mutations Other than G719X/L861Q/S768I. Cancer Control 2025; 32 doi: 10.1177/10732748251386133
|
| 4 |
William Shaffer, Ikei S. Kobayashi, Daniel Sentana-Lledo, Shriram Sundararaman, Meghan D. Lee, Deepa Rangachari, Paul A. VanderLaan, Susumu S. Kobayashi, Daniel B. Costa. EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors. Lung Cancer 2023; 181: 107250 doi: 10.1016/j.lungcan.2023.107250
|
| 5 |
İsmet Seven, Fahriye Tuğba Köş, Hayriye Tatli Doğan, Mustafa Hayri Kişlal, Serhat Sekmek, İrfan Karahan, Selin Aktürk Esen, Doğan Uncu. A rare EGFR exon 19 insertion mutation in metastatic lung adenocarcinoma: a favorable response to afatinib. Anti-Cancer Drugs 2024; doi: 10.1097/CAD.0000000000001671
|